---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-22-010401"
form_type: "8-K"
ticker: "AYTU"
cik: "0001385818"
company_name: "AYTU BIOPHARMA, INC"
filed_at: "2022-06-29T23:59:59+00:00"
generated_at: "2026-06-24T22:19:00.342570+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Aytu BioPharma appoints Vivian Liu to board of directors effective July 1, 2022

## Summary
- Vivian Liu appointed to Aytu's board as independent director and member of Nominating & Corporate Governance Committee.
- Liu receives initial grant of 6,500 restricted shares; one-third vests July 1, 2023, remainder over eight quarters.
- Liu previously served as President/CEO/CFO of Innovus Pharmaceuticals (acquired by Aytu in Feb 2020) and other biopharma firms.
- CEO Josh Disbrow highlights Liu's clinical and corporate development expertise to support company's growth strategy.

## SEC filing metadata
- accession: 0001558370-22-010401
- form_type: 8-K
- ticker: AYTU
- cik: 0001385818
- company_name: AYTU BIOPHARMA, INC
- filed_at: 2022-06-29T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1385818/000155837022010401/0001558370-22-010401-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1385818/000155837022010401/aytu-20220624x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-22-010401
- JSON: https://secwatch.observer/filing/0001558370-22-010401.json
- Plain text: https://secwatch.observer/filing/0001558370-22-010401.txt

## Key facts
- Executive change
  Vivian Liu was appointed as Director at AYTU BIOPHARMA, INC.
  - Action: appointed
  - Role: Director
  source text: On June 24 2022, the Board of Directors of Aytu BioPharma, Inc. (the “Company”) appointed Vivian Liu to the Board of Directors, effective July 1, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1385818/000155837022010401/0001558370-22-010401-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.